Nouscom nouscom.com

Nouscom is a clinical-stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer immunotherapies. Nouscom’s proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and clinically demonstrated to safely and potently harness the power of the immune system.

Nouscom is currently advancing the clinical development of its wholly owned programs including NOUS-209, an off-the-shelf cancer immunotherapy for the treatment of MSI solid tumors or potential to ‘intercept cancer’ in Lynch Syndrome carriers, and NOUS-PEV, a personalized cancer immunotherapy